Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Although the recently licensed shingles vaccine is recommended for older people (age, ≥60), some patients ask, "How likely am I to get shingles?" before deciding whether to be vaccinated. To ...

Potential therapeutic targets to address monocyte and macrophage involvement in IIMs include anti-CCR2, anti-GM-CSF, anti-CSF-1R, Nrf2 activators, PPAR-γ agonists, mesenchymal stem cell-derived ...

Figure 1. TNFSF and receptor-ligand complex formation. The structure of TNFSF (light purple) in its unbound state (left), followed by its binding to the TNFSF receptor (green, blue, and pink) (middle) ...